Disposition of Ifosfamide in Patients Receiving Ifosfamide Infusion Therapy for the Treatment of Cervical Carcinoma
Overview
Affiliations
The disposition of ifosfamide was investigated in nine patients receiving a total of 23 72-h infusions. There was no linear relationship between steady-state plasma concentrations and either vomiting or CNS toxicity. The steady-state plasma concentrations were reproducible within patients, but there was a wide variation between patients. The progress of the disease did not affect the disposition of ifosfamide.
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
Kerbusch T, de Kraker J, Keizer H, Van Putten J, Groen H, Jansen R Clin Pharmacokinet. 2001; 40(1):41-62.
PMID: 11236809 DOI: 10.2165/00003088-200140010-00004.
Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.
Mohrmann M, Ansorge S, Schmich U, Schonfeld B, Brandis M Pediatr Nephrol. 1994; 8(2):157-63.
PMID: 7517170 DOI: 10.1007/BF00865466.
The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.
Lewis L, Fitzgerald D, Mohan P, Thatcher N, Harper P, Rogers H Br J Clin Pharmacol. 1991; 31(1):77-82.
PMID: 2015174 PMC: 1368415. DOI: 10.1111/j.1365-2125.1991.tb03860.x.
Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.
Boos J, Welslau U, Ritter J, Blaschke G, Schellong G Cancer Chemother Pharmacol. 1991; 28(6):455-60.
PMID: 1934249 DOI: 10.1007/BF00685822.
Lewis L Invest New Drugs. 1991; 9(4):305-11.
PMID: 1804803 DOI: 10.1007/BF00183570.